Read Time:9 Second
Moderna Inc.’s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
